Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity.
Thirty-eight of 295 subjects participating in a randomized, double-blind, placebo-controlled trial of the efficacy of daily administration of atovaquone/proguanil for malaria prevention developed malaria at some time during the 20-week prophylaxis period. These subjects (3 atovaquone/proguanil recip...
Egile Nagusiak: | Lacy, MD, Maguire, J, Barcus, M, Ling, J, Bangs, M, Gramzinski, R, Basri, H, Sismadi, P, Miller, G, Chulay, J, Fryauff, D, Hoffman, S, Baird, J |
---|---|
Formatua: | Journal article |
Hizkuntza: | English |
Argitaratua: |
2002
|
Antzeko izenburuak
-
Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia.
nork: Ling, J, et al.
Argitaratua: (2002) -
Primary infection by Plasmodium falciparum or P. vivax in a cohort of Javanese migrants to Indonesian Papua.
nork: Barcus, M, et al.
Argitaratua: (2003) -
Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports.
nork: Färnert, A, et al.
Argitaratua: (2003) -
Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria.
nork: McKeage, K, et al.
Argitaratua: (2003) -
Inhibition of the mosquito transmission of Plasmodium berghei by Malarone (atovaquone-proguanil).
nork: Butcher, G, et al.
Argitaratua: (2000)